Detalhe da pesquisa
1.
Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction.
N Engl J Med
; 381(17): 1609-1620, 2019 10 24.
Artigo
Inglês
| MEDLINE | ID: mdl-31475794
2.
Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure.
Circulation
; 141(5): 352-361, 2020 02 04.
Artigo
Inglês
| MEDLINE | ID: mdl-31736342
3.
Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF.
Circulation
; 141(5): 338-351, 2020 02 04.
Artigo
Inglês
| MEDLINE | ID: mdl-31736337
4.
A putative placebo analysis of the effects of sacubitril/valsartan in heart failure across the full range of ejection fraction.
Eur Heart J
; 41(25): 2356-2362, 2020 07 01.
Artigo
Inglês
| MEDLINE | ID: mdl-32221596
5.
Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF.
Eur Heart J
; 38(15): 1132-1143, 2017 04 14.
Artigo
Inglês
| MEDLINE | ID: mdl-28158398
6.
Importance of Clinical Worsening of Heart Failure Treated in the Outpatient Setting: Evidence From the Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial (PARADIGM-HF).
Circulation
; 133(23): 2254-62, 2016 Jun 07.
Artigo
Inglês
| MEDLINE | ID: mdl-27143684
7.
Angiotensin-neprilysin inhibition versus enalapril in heart failure.
N Engl J Med
; 371(11): 993-1004, 2014 Sep 11.
Artigo
Inglês
| MEDLINE | ID: mdl-25176015
8.
The effects of sacubitril/valsartan on coronary outcomes in PARADIGM-HF.
Am Heart J
; 188: 35-41, 2017 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-28577679
9.
Geographic variations in the PARADIGM-HF heart failure trial.
Eur Heart J
; 37(41): 3167-3174, 2016 Nov 01.
Artigo
Inglês
| MEDLINE | ID: mdl-27354044
10.
Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure.
Circulation
; 131(1): 54-61, 2015 Jan 06.
Artigo
Inglês
| MEDLINE | ID: mdl-25403646
11.
Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF.
Eur Heart J
; 36(38): 2576-84, 2015 Oct 07.
Artigo
Inglês
| MEDLINE | ID: mdl-26231885
12.
Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients.
Eur Heart J
; 36(30): 1990-7, 2015 Aug 07.
Artigo
Inglês
| MEDLINE | ID: mdl-26022006
13.
A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure.
Eur Heart J
; 36(7): 434-9, 2015 Feb 14.
Artigo
Inglês
| MEDLINE | ID: mdl-25416329
14.
Prevalent and Incident Anemia in PARADIGM-HF and the Effect of Sacubitril/Valsartan.
JACC Heart Fail
; 11(7): 749-759, 2023 07.
Artigo
Inglês
| MEDLINE | ID: mdl-37407154
15.
Iron indices and intravenous ferumoxytol: time to steady-state.
Ann Pharmacother
; 46(10): 1308-14, 2012 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-22968523
16.
Natriuretic peptide-based inclusion criteria in heart failure with preserved ejection fraction clinical trials: insights from PARAGON-HF.
Eur J Heart Fail
; 24(4): 672-677, 2022 04.
Artigo
Inglês
| MEDLINE | ID: mdl-35080787
17.
Sacubitril/Valsartan and Frailty in Patients With Heart Failure and Preserved Ejection Fraction.
J Am Coll Cardiol
; 80(12): 1130-1143, 2022 09 20.
Artigo
Inglês
| MEDLINE | ID: mdl-36050227
18.
Diabetes and pre-diabetes in patients with heart failure and preserved ejection fraction.
Eur J Heart Fail
; 24(3): 497-509, 2022 03.
Artigo
Inglês
| MEDLINE | ID: mdl-34918855
19.
Worsening Heart Failure Episodes Outside a Hospital Setting in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial.
JACC Heart Fail
; 9(5): 374-382, 2021 05.
Artigo
Inglês
| MEDLINE | ID: mdl-33839075
20.
Incidence and Outcomes of Pneumonia in Patients With Heart Failure.
J Am Coll Cardiol
; 77(16): 1961-1973, 2021 04 27.
Artigo
Inglês
| MEDLINE | ID: mdl-33888245